FDA Approves Latuda (lurasidone HCl) for Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- March 6, 2018 -- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) that expands the use of Latuda...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Bipolar | Depression | Drugs & Pharmacology | Food and Drug Administration (FDA) | Mania | New Drug Applications | Pediatrics